Search results for "Viral hepatiti"

showing 10 items of 133 documents

Hepatitis B and hepatitis C virus infections in dermatological patients in west Sicily: a seroepidemiological study

2002

Objectives To evaluate the relative frequencies and molecular epidemiological features of viral hepatitis types B and C in dermatological patients in our geographical area. Methods We determined the hepatitis B virus (HBV) and hepatitis C virus (HCV) antibodies and the hepatitis B virus surface antigen (HBsAg) in a cohort of 677 dermatological patients admitted to the Department of Dermatology of Palermo. An 8-mL blood sample was taken from all subjects. The following assays were used: HBsAg, anti-HB core (antigen) (anti-HBc), anti-HB surface (antigen) (anti-HBs), anti-HB early (antigen) (anti-Hbe) and anti-HCV antibodies using enzyme-linked immunosorbent assay. Results One hundred and eigh…

AdultMaleHBsAgAdolescentHepatitis C virusEnzyme-Linked Immunosorbent AssayDermatologyAntibodies Viralmedicine.disease_causeAntigenSeroepidemiologic StudiesmedicineHumansChildSicilyAgedAged 80 and overHepatitis B virusLiver infectionbiologybusiness.industryInfantvirus diseasesMiddle AgedHepatitis BHepatitis Bmedicine.diseaseHepatitis Cdigestive system diseasesInfectious DiseasesChild PreschoolImmunologybiology.proteinFemaleAntibodybusinessViral hepatitisJournal of the European Academy of Dermatology and Venereology
researchProduct

Familiar clustering and spreading of hepatitis delta virus infection

1985

The prevalence of hepatitis delta virus (HDV) infection was significantly higher among the relatives of 79 carriers of HBsAg with antibody to HDV (index cases) than among relatives of 111 carriers without serological evidence of HDV infection (controls). Antibody to HDV was found in 45 of the 80 (56%) carriers of HBsAg in families of index cases but only in 2 of 59 (3%) carriers in families of controls (P less than 0.0001). During follow-up new HDV infection developed in 31% of 13 susceptible carriers in families of index cases, but only in 1.2% of 162 susceptible carriers in families of controls (P less than 0.001). None of the family members previously unexposed to the hepatitis B virus h…

AdultMaleHBsAgvirusesmedicine.disease_causeVirusmedicineHumansHepatitis B virusHepatologybiologyInfantvirus diseasesbiochemical phenomena metabolism and nutritionHepatitis BHepatitis Bmedicine.diseaseHepatitis DVirologyHepatitis DChild PreschoolCarrier StateImmunologybiology.proteinFemaleViral diseaseAntibodyViral hepatitisFollow-Up Studies
researchProduct

Early neutralizing and glycoprotein B (gB)-specific antibody responses to human cytomegalovirus (HCMV) in immunocompetent individuals with distinct c…

2000

Abstract Background: Antibodies with functional anti-Human Cytomegalovirus (HCMV) activity are likely to be involved in preventing virus dissemination and thus may contribute to minimize the clinical manifestations of infection. Objectives: To investigate the role of humoral immunity in modulating the clinical expression of primary Human Cytomegalovirus (HCMV) infection in immunocompetent persons. Study design: Neutralizing (NA) and glycoprotein B (gB)-specific antibodies were quantitated in acute-phase and late-convalescence phase sera from 19 individuals who developed either HCMV mononucleosis (12) or oligosymptomatic hepatitis (seven). Results: The levels of NA in sera drawn early after …

AdultMaleHuman cytomegalovirusAdolescentHepatitis Viral HumanMononucleosisvirusesAntibody AffinityCongenital cytomegalovirus infectionBiologyAntibodies ViralViral Envelope ProteinsNeutralization TestsVirologymedicineHumansAvidityInfectious MononucleosisChildmedicine.diseaseVirologyInfectious DiseasesChild PreschoolImmunoglobulin GCytomegalovirus InfectionsDNA ViralHumoral immunityImmunologybiology.proteinFemaleAntibodyViral hepatitisImmunocompetenceViral loadJournal of Clinical Virology
researchProduct

Impact of HBV genotypes A and D genetic variability on infection evolution

2015

HBV is characterized by a high genetic variability, which is the basis of its classification into eight genotypes (A-H). HBV infection is associated with different outcomes, from self-limiting acute hepatitis to active chronic hepatitis, asymptomatic carriage, and occult infection. The aim of this study was to analyze the genetic variability of HBV genotypes A and D isolates from 79 cases of self-limiting acute hepatitis and chronic hepatitis, in order to identify HBV variants associated with resolution or chronicity of acute HBV infection. The entire preS-S sequence and a fragment of 346 bp of the preC-C region, containing Enhancer II and Basal Core Promoter sequences, were analyzed. A phy…

AdultMaleMicrobiology (medical)Hepatitis B virusSettore MED/07 - Microbiologia E Microbiologia ClinicaGenotypeAcute hepatitis BBiologymedicine.disease_causeMicrobiologyLiver diseaseViral ProteinspreC/C mutationGeneticImmune-escape mutationGenetic variationGenotypeGeneticsmedicineHumansViral ProteinGenetic variabilityMolecular BiologyEcology Evolution Behavior and SystematicsPhylogenyAgedHepatitis B virusPolymorphism GeneticpreS/S mutationGenetic VariationHepatitis B viruHepatitis BMiddle Agedmedicine.diseaseHepatitis BVirologyBiological EvolutionEcology Evolution Behavior and SystematicInfectious DiseasesAmino Acid SubstitutionViral evolutionImmunologyMutationFemaleViral hepatitisHuman
researchProduct

Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up.

1998

Acute infection with hepatitis C virus (HCV) develops into a chronic hepatitis in about 50-70% of patients. Treatment of these patients with interferon-alpha (IFN-alpha) results in a sustained long-term response in only 15-20% but causes numerous unwanted side-effects in a higher percentage of patients. The aim of our study was to define host or viral parameters that would allow identification of responders and non-responders to IFN-alpha prior to the onset of treatment. We studied a group of 87 patients suffering from chronic hepatitis C who were treated with IFN-alpha. After long-term follow-up, 18 patients (21%) showed a sustained response to IFN-alpha therapy (normalization of serum tra…

AdultMaleNecrosisGenotypeHepatitis C virusAlpha interferonInflammationHepacivirusmedicine.disease_causeAntiviral AgentsFibrosisVirologyGenotypemedicineHumansViremiaHepatologymedicine.diagnostic_testbusiness.industryTumor Necrosis Factor-alphaInterferon-alphaHLA-DR AntigensHepatitis C ChronicMiddle AgedViral Loadmedicine.diseaseInfectious DiseasesTreatment OutcomeLiver biopsyImmunologyRNA ViralFemalemedicine.symptombusinessViral hepatitisFollow-Up StudiesJournal of viral hepatitis
researchProduct

The human hepatic asialoglycoprotein receptor is a target antigen for liver-infiltrating T cells in autoimmune chronic active hepatitis and primary b…

1990

Autoantibodies to the human hepatic asialoglycoprotein receptor have been found in nearly 50% of the sera of patients with autoimmune chronic active hepatitis and in 15% of patients with primary biliary cirrhosis. In this study we demonstrate that the human hepatic asialoglycoprotein receptor is also a target antigen for T cell-mediated immune responses. Peripheral blood lymphocytes of 37% (7 of 19) of patients with autoimmune chronic active hepatitis and 33% (2 of 6) of patients with primary biliary cirrhosis showed a proliferative response to highly purified human hepatic asialoglycoprotein receptor, whereas no proliferation was found with peripheral blood lymphocytes of patients with chr…

AdultMaleT-LymphocytesAsialoglycoprotein ReceptorLymphocyte Activationdigestive systemAutoantigensAutoimmune DiseasesPrimary biliary cirrhosisAntigenmedicineHumansHepatic Asialoglycoprotein ReceptorReceptors ImmunologicHepatitis ChronicHepatitisAutoimmune diseaseHepatologymedicine.diagnostic_testbusiness.industryLiver Cirrhosis BiliaryHLA-DR AntigensMiddle Agedmedicine.diseaseLiverLiver biopsyImmunologyAsialoglycoprotein receptorbusinessViral hepatitisHepatology (Baltimore, Md.)
researchProduct

LOW-DOSE INTERLEUKIN-2 INDUCES SYSTEMIC IMMUNE RESPONSES AGAINST HBsAg IN IMMUNODEFICIENT NON-RESPONDERS TO HEPATITIS B VACCINATION

1989

Abstract A metabolic monocyte defect appears to correlate with non-responsiveness to hepatitis B vaccine in many patients on haemodialysis. This defect prevents production of interleukin-2 during T-cell activation after antigen contact. Receptors for interleukin-2 are, however, expressed in greater numbers than in healthy subjects or uraemic responders to hepatitis B vaccination. In this study, ten uraemic patients, previous non-responders to vaccination against hepatitis B, were revaccinated with the same vaccine combined with one intramuscular injection (2·5 × 10 5 U) of natural human interleukin-2. Systemic production of antibodies against hepatitis B surface antigen was initiated in tho…

AdultMaleViral Hepatitis VaccinesInterleukin 2HBsAgHepatitis B vaccinePilot ProjectsImmunoenzyme TechniquesImmune systemAntigenmedicineHumansHepatitis B VaccinesAgedUremiaHepatitis B Surface Antigensbiologybusiness.industryImmunologic Deficiency SyndromesReceptors Interleukin-2General MedicineMiddle AgedHepatitis Bmedicine.diseaseVirologyVaccinationAntibody FormationImmunologybiology.proteinInterleukin-2FemaleAntibodybusinessmedicine.drugThe Lancet
researchProduct

Influence of Thymopentin on Antibody Response, and Monocyte and T Cell Function in Hemodialysis Patients Who Fail to Respond to Hepatitis B Vaccinati…

1990

We investigated the influence of thymopentin as an adjuvant for hepatitis B vaccination on in vitro monocyte and T cell function and in vivo antibody response in a prospective, placebo-controlled double-blind trial in 20 low- and nonresponders to hepatitis B vaccination on chronic hemodialysis. 50 mg thymopentin was given subcutaneously twice per week for 3 weeks, followed by 1 intramuscular injection of 40 micrograms HB-Vax and 3 subsequent injections of thymopentin. After 1 month, the patients were boostered with 40 micrograms HB-Vax. There was no significant difference in T cell and monocyte function after administration of thymopentin, as determined in vitro. After 3 months, 3 patients …

AdultMaleViral Hepatitis VaccinesT-Lymphocytesmedicine.medical_treatmentT cellThymopoietinsMonocytesAdjuvants ImmunologicRenal DialysismedicineHumansThymopentinProspective StudiesHepatitis B AntibodiesAgedRandomized Controlled Trials as TopicAged 80 and overbusiness.industryMonocyteAntibody titerMiddle AgedHepatitis BHepatitis Bmedicine.diseasePeptide FragmentsThymus HormonesVaccinationmedicine.anatomical_structureImmunologyFemaleThymopentinIntramuscular injectionbusinessAdjuvantmedicine.drugNephron
researchProduct

Anti-hepatitis A virus seroprevalence and seroconversion in a cohort of patients with chronic viral hepatitis

2002

Abstract Background. Patients with chronic hepatitis C infected by hepatitis A virus have a substantial risk of fulminant hepatitis or death, while the course of hepatitis A virus is uncomplicated in most subjects with chronic hepatitis B. Aim. To evaluate the prevalence of anti-hepatitis A virus antibodies and the incidence of hepatitis A virus seroconversion in a nationwide sample of 530 patients with chronic hepatitis B and/or hepatitis C infection initially susceptible to this infection after a follow-up of some years. Results. The overall anti-hepatitis A virus prevalence was 85.7%, with no difference between males and females. By the age of 50 years, almost all patients were found to …

AdultMalemedicine.medical_specialtyAdolescentHepatitis C virusmedicine.disease_causeHepatitis A AntibodiesVirusHepatitis B ChronicSeroepidemiologic StudiesInternal medicinemedicineHumansSeroconversionFulminant hepatitisAgedHepatitis B virusHepatologybusiness.industryIncidenceGastroenterologyHepatitis CHepatitis BHepatitis AHepatitis C ChronicMiddle Agedmedicine.diseaseVirologyChronic liver disease; Hepatitis A virus superinfection; Hepatitis B virus; Hepatitis C virus;ItalyHepatitis A AntibodieFemalebusinessViral hepatitisHepatitis A Virus HumanHuman
researchProduct

Clinical features of oral lichen planus. A retrospective study of 65 cases

2010

Objectives: To describe the clinical features of patients diagnosed with oral lichen planus (OLP) and to establish the prevalence of its malignant transformation in our setting. Study design: A retrospective study was made of 65 patients clinically and histologically diagnosed with OLP in the Service of Oral Surgery (Dental Clinic of the University of Barcelona, Spain) in the period 1990-2005. A descriptive and bivariate statistical analysis was made. Results: The mean patient age was 59 years (SD ± 14.9). Most of the patients (61%) were women, and the most frequent location of the lesions was the buccal mucosa (90.8%). White forms of OLP were noted in 66% of the cases, and 46.2% of the pat…

AdultMalemedicine.medical_specialtyAdolescentLichensAlcohol abuseMalalties de la bocaChronic liver diseaseBuccal mucosaYoung AdultHepatitis víricastomatognathic systemDiabetes mellitusStatistical significanceTabacTobaccomedicineHumansLíquensViral hepatitisGeneral DentistryAgedRetrospective StudiesAged 80 and overbusiness.industryRetrospective cohort studyMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologySurgerystomatognathic diseasesMouth diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASPopulation studySurgeryOral lichen planusFemalebusinessLichen Planus Oral
researchProduct